<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1470">
  <stage>Registered</stage>
  <submitdate>9/02/2007</submitdate>
  <approvaldate>9/02/2007</approvaldate>
  <nctid>NCT00434447</nctid>
  <trial_identification>
    <studytitle>Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases</studytitle>
    <scientifictitle>A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CZOL446EAU22</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bone Neoplasms</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Other</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Zoledronic acid

Experimental: Zoledronic Acid - ZOL446


Treatment: drugs: Zoledronic acid


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety assessed by incidence of renal impairment, osteonecrosis of the Jaw (ONJ), adverse events and serious adverse events. Efficacy assessed by incidence of skeletal related events (SREs).</outcome>
      <timepoint>52 weeks</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Documented bone metastases from breast cancer, prostate cancer or multiple myeloma

          -  Prior treatment with zoledronic acid for 1-2 yrs

          -  Life expectancy of at least 6 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Prior treatment with bisphosphonates other than zoledronic acid

          -  Abnormal kidney function

          -  Current or previous dental problems or planned dental surgery

          -  Pregnant or likely to become pregnant during the study

        Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>73</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Canberra</hospital>
    <hospital>Novartis Investigative Site - Concord</hospital>
    <hospital>Novartis Investigative Site - Liverpool</hospital>
    <hospital>Novartis Investigative Site - Wagga Wagga</hospital>
    <hospital>Novartis Investigative Site - Redcliffe</hospital>
    <hospital>Novartis Investigative Site - Townsville</hospital>
    <hospital>Novartis Investigative Site - Woolloongabba</hospital>
    <hospital>Novartis Investigative Site - Ballarat</hospital>
    <hospital>Novartis Investigative Site - Box Hill</hospital>
    <hospital>Novartis Investigative Site - Frankston</hospital>
    <postcode> - Canberra</postcode>
    <postcode> - Concord</postcode>
    <postcode> - Liverpool</postcode>
    <postcode> - Wagga Wagga</postcode>
    <postcode> - Redcliffe</postcode>
    <postcode> - Townsville</postcode>
    <postcode> - Woolloongabba</postcode>
    <postcode> - Ballarat</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Frankston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to monitor the safety and efficacy of long-term treatment with
      zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the
      jaw(ONJ), overall safety and skeletal related events (SREs) beyond 12 months treatment</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00434447</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmeceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>